Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P

21. Januar 2020 aktualisiert von: Philip Morris Products S.A.

A Single-center, Open-label, Randomized, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile, Pharmacodynamics, Safety and Tolerability of Four P3P Variants in Smoking Healthy Adult Subjects

This is a single-center, open-label, randomized, crossover study to evaluate the pharmacokinetic (PK) profiles of four P3P variants (differing in nicotine aerosol particle size, nicotine concentration and in the absence or presence of a flavoring system), following a fixed puffing regimen and an ad libitum use period. In addition, pharmacodynamic (PD) effects (subjective effects and related behavioral assessments), as well as human puffing topography, will be evaluated, to provide further insights on product safety, acceptance, and use.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

The goal of the proposed study is to evaluate the pharmacokinetic profiles of four P3P variants. Variants with two different nicotine contents (1 mg/product and 2 mg/product), two different nicotine aersol particle sizes and presence/absence of a flavoring system will be tested to identify which one would yield plasma nicotine concentrations as close as possible to those achieved after smoking a single cigarette. All of the subjects will initially use the lowest nicotine content product (P3P 3). Subject will continue the study using the three remaining products (P3P 1, P3P 2 and P3P 4) containing 2 mg nicotine/product in a randomly assigned sequence.

Two product use regimens: fixed puffing and ad libitum use will be applied to provide insight into nicotine absorption. The fixed puffing regimen with consistent use conditions across subjects will be applied in order to minimize variability. The 1 hour ad libitum use period will provide information on nicotine PK and product acceptance when subjects use the P3P according to their own puffing behavior which is closer to a real-world setting.

Safety and tolerability will also be assessed throughout the study.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

19

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Schweiz
    • Ticino
      • Arzo, Ticino, Schweiz, 6864
        • CROSS Research

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

21 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion criteria:

  • Subject has signed the Informed Consent Form (ICF) and is able to understand the information provided in the ICF.
  • Subject is between 21 and 65 years old.
  • Subject is Caucasian.
  • Smoking, healthy subject as judged by the Investigator or designee based on available assessments from the screening period.
  • Subject has been smoking at least 10 commercially available cigarettes per day at least for the last 4 weeks prior to Screening Visit. Smoking status will be verified based on a urinary cotinine test (cotinine ≥ 200 ng/mL).
  • Subject has been smoking for at least the last 3 years prior to Screening Visit.
  • Subject does not plan to quit smoking in the next 2 months after the Screening Visit.

Exclusion criteria:

  • Female subject is pregnant or breastfeeding.
  • Female subject uses estrogen-containing hormonal contraception or hormone replacement therapy.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Sonstiges
  • Zuteilung: Zufällig
  • Interventionsmodell: Crossover-Aufgabe
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Product Sequence 1

Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:

P3P 2 on Day 2; P3P 4 on Day 3; P3P 1 on Day 4
Sonstiges: P3P 1
2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Sonstiges: P3P 2
2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Sonstiges: P3P 3
1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Sonstiges: P3P 4
2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
Aktiver Komparator: Product Sequence 2

Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:

P3P 4 on Day 2; P3P 1 on Day 3; P3P 2 on Day 4
Sonstiges: P3P 1
2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Sonstiges: P3P 2
2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Sonstiges: P3P 3
1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Sonstiges: P3P 4
2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
Aktiver Komparator: Product Sequence 3

Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:

P3P 1 on Day 2; P3P 2 on Day 3; P3P 4 on Day 4
Sonstiges: P3P 1
2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Sonstiges: P3P 2
2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Sonstiges: P3P 3
1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Sonstiges: P3P 4
2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
Aktiver Komparator: Product Sequence 4

Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:

P3P 1 on Day 2; P3P 4 on Day 3; P3P 2 on Day 4
Sonstiges: P3P 1
2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Sonstiges: P3P 2
2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Sonstiges: P3P 3
1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Sonstiges: P3P 4
2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
Aktiver Komparator: Product Sequence 5

Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:

P3P 2 on Day 2; P3P 1 on Day 3; P3P 4 on Day 4
Sonstiges: P3P 1
2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Sonstiges: P3P 2
2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Sonstiges: P3P 3
1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Sonstiges: P3P 4
2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
Aktiver Komparator: Product Sequence 6

Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:

P3P 4 on Day 2; P3P 2 on Day 3; P3P 1 on Day 4
Sonstiges: P3P 1
2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Sonstiges: P3P 2
2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Sonstiges: P3P 3
1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Sonstiges: P3P 4
2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Plasma Nicotine Concentration-time Profile
Zeitfenster: Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
To measure the plasma nicotine concentration-time profile of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.
Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
Maximum Plasma Concentration [Cmax]
Zeitfenster: Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
To measure the maximum nicotine plasma concentration [Cmax] of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.
Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
Time to the Maximum Nicotine Concentration [Tmax]
Zeitfenster: Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
To measure the time to maximum nicotine concentration [Tmax] of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.
Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
Area Under the Concentration-time Curve From Start of Product Use (T0 Fix) to 4 Hours [AUCfix (0-4h)]
Zeitfenster: Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
To measure the area under the plasma concentration-time curve of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.
Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Plasma Nicotine Concentration-time Profile
Zeitfenster: Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
To measure the plasma nicotine concentration-time profile of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.
Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
Peak Plasma Nicotine Concentration [Cpeak]
Zeitfenster: Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
To measure the Peak plasma nicotine concentration [Cpeak] of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.
Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
Time to Peak Plasma Nicotine Concentration [Tpeak]
Zeitfenster: Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
To measure the time to peak plasma nicotine concentration [Tpeak] of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.
Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
Trough Plasma Nicotine Concentration [Ctrough]
Zeitfenster: Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
To measure the trough plasma nicotine concentration [Ctrough] of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.
Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
Average of Plasma Nicotine Concentration From T0 ad Lib to 1 Hour [Caverage]
Zeitfenster: Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour during ad libitum use) on Days 1, 2, 3 and 4
To measure the average of plasma nicotine concentration [Caverage], of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels
Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour during ad libitum use) on Days 1, 2, 3 and 4
Area Under the Concentration-time Curve From Start of Product Use (T0 ad Lib) to 4 Hours [AUCad Lib (0-4h)]
Zeitfenster: Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
To measure the area under the plasma concentration-time curve of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.
Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
AUC of Craving for a Cigarette During and After the Fixed Puffing Regimen
Zeitfenster: During and up to 4 hours post-product use on days 1, 2, 3 and 4
Measured on a Visual Analogue Scale (VAS) of 0 (no craving) to 100 (strong craving).
During and up to 4 hours post-product use on days 1, 2, 3 and 4
AUC Craving for a Cigarette During and After the ad Libitum Use Period
Zeitfenster: During and up to 4 hours post-product use on days 1, 2, 3 and 4
Measured on a Visual Analogue Scale (VAS) of 0 (no craving) to 100 (strong craving).
During and up to 4 hours post-product use on days 1, 2, 3 and 4
Product Evaluation
Zeitfenster: Within 60 minutes after the ad libitum use session on days 1, 2, 3 and 4
Measured with an adapted version of the modified Cigarette Evaluation Questionnaire (adapted mCEQ) following the ad libitum use period. Assessed on a 7-point scale, ranging from 1 (not at all) to 7 (extremely).
Within 60 minutes after the ad libitum use session on days 1, 2, 3 and 4
Sensory Parameters
Zeitfenster: Within 60 minutes after the ad libitum use session on days 1, 2, 3 and 4
Measured with a Sensory Questionnaire (SQ) following the ad libitum use period. Response to each question is assessed on a 7-point scale, ranging from 1 (not at all) to 7 (extremely).
Within 60 minutes after the ad libitum use session on days 1, 2, 3 and 4
Human Puffing Topography (HPT) Parameters (Puff Volume) of Four P3P Variants During the Fixed Puffing Regimen Period.
Zeitfenster: During fixed puffing product use on days 1, 2, 3 and 4
Descriptive statistics of total puff volume and average puff volume, of four P3P variants, during the fixed puffing regimen period.
During fixed puffing product use on days 1, 2, 3 and 4
Human Puffing Topography (HPT) Parameters (Puff Volume) of Four P3P Variants During the ad Libitum Use Period.
Zeitfenster: During ad libitum product use on days 1, 2, 3 and 4
Descriptive statistics of total puff volume and average puff volume, of four P3P variants, during the ad libitum use period.
During ad libitum product use on days 1, 2, 3 and 4
Amount of Powder Aerosolized From P3P From the Fixed Puffing Regimen.
Zeitfenster: Before and after fixed puffing product use on days 1, 2, 3 and 4
Descriptive statistics of P3P weight before use, and after use, for the fixed puffing regimen.
Before and after fixed puffing product use on days 1, 2, 3 and 4
Amount of Powder Aerosolized From P3P From the ad Libitum Use Period (Per Product Used).
Zeitfenster: Before and after ad libitum product use on days 1, 2, 3 and 4
P3P weight before use, and after use, to determine the amount of powder aerosolized from P3P during Ad Libitum use (per product used).
Before and after ad libitum product use on days 1, 2, 3 and 4

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Philip Morris Products S.A.

Ermittler

  • Hauptermittler: Milko Radicioni, MD, CROSS Research, Arzo, Ticino, Switzerland

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

7. November 2017

Primärer Abschluss (Tatsächlich)

1. Februar 2018

Studienabschluss (Tatsächlich)

2. Mai 2018

Studienanmeldedaten

Zuerst eingereicht

22. November 2017

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

5. Dezember 2017

Zuerst gepostet (Tatsächlich)

12. Dezember 2017

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

31. Januar 2020

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

21. Januar 2020

Zuletzt verifiziert

1. Januar 2020

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • P3P-PK-01-CH

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur P3P 1

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Hong Kong

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren